Inclusion Criteria:

          -  Participant must be HLA-A2+. Retesting is not required for patients who have previous
             documented positivity

          -  Have IO-refractory melanoma with primary PD1-resistance. Note: Any lines of prior
             therapies are allowed, but the last line needs to include an anti PD-1 or anti PD-L1
             agent. The prior treatments may include any standard and/or experimental therapies

          -  Have >= 1 tumor site amenable to core needle biopsy that is not the site of disease
             used to measure antitumor response

          -  Have measurable disease based on RECIST 1.1 criteria present

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Platelets >= 75,000/microliter

          -  Hemoglobin >= 9 g/deciliter

          -  Absolute neutrophil count (ANC) >= 1500/microliter

          -  Creatinine < 1.5 x institutional upper limit of normal (ULN) OR creatinine clearance
             >= 50 mL/min by Cockcroft-Gault formula for subjects with creatinine levels >= 1.5 x
             ULN

          -  Total bilirubin not greater than 1.5 x institutional ULN, except for patients with
             known Gilbert's Syndrome, who are eligible to no more than 2 x institutional ULN

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) no
             greater than 3 x institutional ULN OR, no greater than 5 x ULN for subjects with liver
             metastases

          -  Participants of child-bearing potential must agree to use adequate contraceptive
             methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study
             entry. Should a woman become pregnant or suspect she is pregnant while she or her
             partner is participating in this study, she should inform her treating physician
             immediately

          -  Participant or legal representative must understand the investigational nature of this
             study and sign an Independent Ethics Committee/Institutional Review Board approved
             written informed consent form prior to receiving any study related procedure

          -  Candidate for resumption of anti-PD1/PD-L1 or anti-CTLA4 therapy

        Exclusion Criteria:

          -  Is currently being treated with systemic immunosuppressive agents, including steroids:
             Subjects will be ineligible until 3 weeks after removal from immunosuppressive
             treatments, except when they are administered as replacement therapy for endocrine
             dysfunction (and receive no more than 10 mg prednisone or equivalent: inhaled steroids
             are allowed)

          -  Has had prior anti-cancer therapy within 2 weeks prior to study day 1 or who has not
             recovered (i.e., no more than grade 1 or at baseline) from adverse events due to a
             previously administered agent, except for neuropathy (no more than grade 2) or
             alopecia or vitiligo (any grade)

          -  Has a known additional malignancy that is progressing or requires active treatment

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Treated brain metastases are allowed, if stable for more than 4 weeks

          -  Has a history of cardiac event(s) (acute coronary syndrome, myocardial infarction, or
             ischemia (within 3 months of signing consent) or, subject has a New York Heart
             Association classification of III or IV

          -  Has an active infection requiring systemic therapy

          -  Has known active hepatitis B or hepatitis C infection

          -  Has known immunosuppressive disease (e.g. human immunodeficiency virus [HIV], acquired
             immunodeficiency syndrome [AIDS] or other immune depressing disease). Testing is not
             mandatory

          -  Has known serious hypersensitivity reactions to pegylated (peg)-interferon alpha-2b or
             interferon alpha-2b

          -  Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or
             nonsteroidal anti-inflammatory drugs (NSAIDs)

          -  Has received a blood transfusion in the two weeks prior to leukapheresis

          -  Women of child bearing potential who are pregnant or nursing

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the Investigator?s opinion deems the participant an unsuitable
             candidate or unacceptable risk to receive study drug regimen

          -  Patients who showed initial response to PD1 blockade and developed secondary
             resistance